CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 2 enrolled
Drug / intervention
Avapritinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04825574
NCT04825574Phase 4Completed
CompareCT.gov

Extension Protocol for Patients Previously Treated in Avapritinib Clinical Trials

Blueprint Medicines Corporation·interventional·Posted Apr 1, 2021·Updated Nov 26, 2024

In Brief

A Phase 4 clinical trial evaluating Avapritinib for Gastrointestinal Stromal Tumors. Completed, enrolled 2 participants across 1 site.

Detailed Summary

This is an open-label extension study to provide long term safety data for GIST patients who are deriving clinical benefit from avapritinib upon the completion of avapritinib clinical trials.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Stromal Tumors
CountriesFrance
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedApr 1, 2021
Enrollment StartMay 21, 2021
Primary CompletionNov 23, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.3 years ago

Interventions

Avapritinibdrug

avapritinib tablet